Aldeyra Therapeutics 3Q 2026: EPS ($0.06) — 10-Q Summary

Aldeyra Therapeutics reported a narrower net loss in the third quarter as operating expenses declined, primarily reflecting lower external clinical development, personnel, manufacturing, preclinical and consulting costs. The company said the reduction reflected a shift from clinical development tow…